Skip to main content
SpringerLink
Log in

Dosimetric Approaches: Current Concepts

  • Chapter
  • First Online:
Practical Management of Thyroid Cancer

  • 1225 Accesses

Abstract

Radioiodine therapy with radioactive iodine I-131 is an integral component in the treatment of patients with malignant thyroid disease. Individual dosimetry is useful both therapeutically for the assessment of the associated absorbed doses to the tumour/metastases as well as in selected patients to pre-therapeutically determine the activities to be administered. National and international guidelines recommend methods and mathematical procedures that are applicable for dosimetry, but leave the treating physician unsupported in the interpretation of the results and the therapeutic consequences. The current article provides an overview of the basic principles and methods of dosimetry and indicates how dosimetric assessments in radioiodine therapy can influence the treatment of thyroid carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59. https://doi.org/10.1007/s00259-008-0883-1.

    Article  CAS  PubMed  Google Scholar 

  2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.

    Article  CAS  PubMed  Google Scholar 

  4. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405–12. https://doi.org/10.1007/s00259-008-0761-x.

    Article  PubMed  Google Scholar 

  5. Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC, Bolch WE, et al. MIRD pamphlet No. 24: guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med. 2013;54(12):2182–8. https://doi.org/10.2967/jnumed.113.122390.

    Article  CAS  PubMed  Google Scholar 

  6. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53(8):1310–25. https://doi.org/10.2967/jnumed.111.100123.

    Article  CAS  PubMed  Google Scholar 

  7. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37s–61s.

    CAS  PubMed  Google Scholar 

  8. Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45(4):619–25.

    PubMed  Google Scholar 

  9. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation-dose and outcome of radioiodine therapy for thyroid-cancer. New Engl J Med. 1983;309(16):937–41. https://doi.org/10.1056/Nejm198310203091601.

    Article  CAS  PubMed  Google Scholar 

  10. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451–6.

    CAS  PubMed  Google Scholar 

  11. Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53(5):546–61.

    CAS  PubMed  Google Scholar 

  12. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):270–5. https://doi.org/10.1007/s00259-009-1261-3.

    Article  CAS  PubMed  Google Scholar 

  13. Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using I-124 PET imaging. J Nucl Med. 2014;55(11):1759–65. https://doi.org/10.2967/jnumed.114.144089.

    Article  CAS  PubMed  Google Scholar 

  14. Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, et al. Efficacy of dosimetric versus empiric prescribed activity of I-131 for therapy of differentiated thyroid cancer. J Clin Endocrinol Metabol. 2011;96(10):3217–25. https://doi.org/10.1210/jc.2011-0494.

    Article  CAS  Google Scholar 

  15. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy, Nucl Med. 1962;87:171–82.

    CAS  Google Scholar 

  16. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47(10):1587–91.

    PubMed  Google Scholar 

  17. Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16(10):1019–23. https://doi.org/10.1089/thy.2006.16.1019.

    Article  CAS  PubMed  Google Scholar 

  18. Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Spath G, et al. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med. 1996;37(9):1496–503.

    CAS  PubMed  Google Scholar 

  19. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648–54.

    PubMed  Google Scholar 

  20. Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, et al. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Ann Nucl Med. 2012;26(9):723–9. https://doi.org/10.1007/s12149-012-0632-1.

    Article  CAS  PubMed  Google Scholar 

  21. Giostra A, Richetta E, Pasquino M, Miranti A, Cutaia C, Brusasco G, et al. Red marrow and blood dosimetry in I-131 treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results. Phys Med Biol. 2016;61(11):4316–26. https://doi.org/10.1088/0031-9155/61/11/4316.

    Article  CAS  PubMed  Google Scholar 

  22. Verburg FA, Lassmann M, Mader U, Luster M, Reiners C, Hanscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered I-131 activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2011;38(4):673–80. https://doi.org/10.1007/s00259-010-1689-5.

    Article  CAS  PubMed  Google Scholar 

  23. Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with I-131 by use of I-124 PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48(1):143–9.

    CAS  PubMed  Google Scholar 

  24. Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2009;16(4):1283–9. https://doi.org/10.1677/Erc-09-0076.

    Article  PubMed  Google Scholar 

  25. de Keizer B, Brans B, Hoekstra A, Zelissen PMJ, Koppeschaar HPF, Lips CJM, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging. 2003;30(3):367–73. https://doi.org/10.1007/s00259-002-1076-y.

    Article  CAS  PubMed  Google Scholar 

  26. Verburg FA, Mader U, Reiners C, Hänscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical I-131 therapy in both high- and low-risk patients. J Clin Endocrinol Metabol. 2014;99(12):4487–96. https://doi.org/10.1210/jc.2014-1631.

  27. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45(8):1366–72.

    CAS  PubMed  Google Scholar 

  28. Thies ED, Tanase K, Maeder U, Luster M, Buck AK, Hanscheid H, et al. The number of I-131 therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(12):2281–90. https://doi.org/10.1007/s00259-014-2851-2.

    Article  PubMed  Google Scholar 

  29. Lee JJ, Chung JK, Kim SE, Kang WJ, Park do J, Lee DS, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22(9):727–34. https://doi.org/10.1007/s12149-007-0179-8.

    Article  PubMed  Google Scholar 

  30. Verburg FA, Stokkel MPM, Duren C, Verkooijen RBT, Mader U, van Isselt JW, et al. No survival difference after successful I-131 ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):276–83. https://doi.org/10.1007/s00259-009-1315-6.

    Article  PubMed  Google Scholar 

  31. Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, et al. Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med. 2016. https://doi.org/10.2967/jnumed.116.179606.

  32. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol. 1994;39(6):961–81.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

    Michael Lassmann & Heribert Hänscheid

  2. Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany

    Markus Luster

Authors
  1. Michael Lassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Luster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heribert Hänscheid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lassmann .

Editor information

Editors and Affiliations

  1. Consultant (Hon), Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK

    Ujjal K. Mallick

  2. London, UK

    Clive Harmer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lassmann, M., Luster, M., Hänscheid, H. (2018). Dosimetric Approaches: Current Concepts. In: Mallick, U.K., Harmer, C. (eds) Practical Management of Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-91725-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91725-2_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91724-5

  • Online ISBN: 978-3-319-91725-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation